News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
93,793 Results
Type
Article (6810)
Company Profile (39)
Press Release (86944)
Multimedia
Podcasts (6)
Webinars (1)
Section
Business (27896)
Career Advice (130)
Deals (4010)
Drug Delivery (32)
Drug Development (14175)
Employer Resources (12)
FDA (2899)
Job Trends (2141)
News (49529)
Policy (6039)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (432)
Accelerated approval (3)
Adcomms (7)
Allergies (32)
Alliances (9054)
ALS (13)
Alzheimer's disease (264)
Antibody-drug conjugate (ADC) (45)
Approvals (2898)
Artificial intelligence (46)
Autoimmune disease (9)
Automation (3)
Bankruptcy (19)
Best Places to Work (1823)
BIOSECURE Act (16)
Biosimilars (78)
Biotechnology (26)
Bladder cancer (25)
Brain cancer (6)
Breast cancer (60)
Cancer (488)
Cardiovascular disease (22)
Career advice (113)
Career pathing (3)
CAR-T (21)
Cell therapy (84)
Cervical cancer (3)
Clinical research (11586)
Collaboration (194)
Compensation (44)
Complete response letters (9)
COVID-19 (545)
CRISPR (5)
C-suite (52)
Cystic fibrosis (13)
Data (449)
Denatured (2)
Depression (6)
Diabetes (37)
Diagnostics (569)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (26)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (9607)
Editorial (6)
Employer branding (3)
Employer resources (10)
Events (11949)
Executive appointments (124)
FDA (3252)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (150)
Gene editing (25)
Generative AI (6)
Gene therapy (85)
GLP-1 (110)
Government (1324)
Grass and pollen (1)
Guidances (12)
Healthcare (1958)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (43)
Indications (9)
Infectious disease (581)
Inflammatory bowel disease (48)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (12)
Interviews (11)
IPO (1836)
IRA (13)
Job creations (387)
Job search strategy (108)
Kidney cancer (2)
Labor market (2)
Layoffs (55)
Leadership (1)
Legal (562)
Liver cancer (13)
Lung cancer (77)
Lymphoma (30)
Machine learning (1)
Management (2)
Manufacturing (114)
MASH (12)
Medical device (1199)
Medtech (1200)
Mergers & acquisitions (2274)
Metabolic disorders (88)
Multiple sclerosis (18)
NASH (2)
Neurodegenerative disease (18)
Neuropsychiatric disorders (1)
Neuroscience (340)
NextGen: Class of 2025 (702)
Non-profit (350)
Northern California (488)
Now hiring (11)
Obesity (32)
Opinion (48)
Ovarian cancer (20)
Pain (9)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (32)
Patient recruitment (19)
Peanut (21)
People (8024)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (3805)
Phase II (4821)
Phase III (4254)
Pipeline (306)
Policy (52)
Postmarket research (297)
Preclinical (1486)
Press Release (66)
Prostate cancer (19)
Psychedelics (5)
Radiopharmaceuticals (37)
Rare diseases (73)
Real estate (924)
Recruiting (4)
Regulatory (4807)
Reports (11)
Research institute (389)
Resumes & cover letters (13)
RNA editing (1)
RSV (11)
Schizophrenia (11)
Series A (35)
Series B (13)
Service/supplier (3)
Sickle cell disease (7)
Southern California (494)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (9)
Startups (576)
State (1)
Stomach cancer (4)
Supply chain (11)
Tariffs (11)
The Weekly (4)
United States (4229)
Vaccines (189)
Venture capitalists (6)
Weight loss (16)
Women's health (3)
Date
Today (16)
Last 7 days (134)
Last 30 days (497)
Last 365 days (6279)
2025 (1998)
2024 (6548)
2023 (7005)
2022 (9135)
2021 (9522)
2020 (8199)
2019 (5879)
2018 (4538)
2017 (5093)
2016 (4649)
2015 (5315)
2014 (3766)
2013 (2930)
2012 (3020)
2011 (3172)
2010 (2597)
Location
Africa (92)
Alabama (11)
Alaska (1)
Arizona (13)
Arkansas (2)
Asia (7585)
Australia (884)
California (1163)
Canada (249)
China (174)
Colorado (35)
Connecticut (26)
Delaware (40)
Europe (13972)
Florida (140)
Georgia (19)
Idaho (13)
Illinois (53)
India (12)
Indiana (40)
Iowa (2)
Japan (33)
Kansas (3)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (320)
Massachusetts (809)
Michigan (24)
Minnesota (45)
Mississippi (1)
Missouri (15)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (464)
New Mexico (4)
New York (329)
North Carolina (200)
North Dakota (7)
Northern California (488)
Ohio (41)
Oklahoma (7)
Oregon (3)
Pennsylvania (191)
Puerto Rico (1)
Rhode Island (5)
South America (136)
South Carolina (2)
Southern California (494)
Tennessee (3)
Texas (156)
Utah (24)
Virginia (18)
Washington D.C. (6)
Washington State (92)
Wisconsin (8)
93,793 Results for "insitu biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ruvidar Demonstrates 7 Year Complete Response
Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response
April 7, 2025
·
6 min read
Business
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVecTM platform.
January 4, 2024
·
5 min read
Business
InSitu Biologics Announces License Agreement With Mayo Clinic For Co-Development of Anti-Cancer Therapeutics
InSitu Biologics, Inc. is pleased to announce that it has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics.
December 22, 2022
·
2 min read
BioMidwest
InSitu Biologics Shares Latest Investigational Work at ASRA Meeting - November 18, 2022
InSitu Biologics, Inc. will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain Medicine Meeting of the American Society of Regional Anesthesia on November 18th , 2022.
November 17, 2022
·
1 min read
Press Releases
Bora Biologics Unveils Cutting-Edge Innovations at Festival of Biologics 2025
April 17, 2025
·
2 min read
Press Releases
Solvias to Speak at Festival of Biologics 2025 on Building Robust CMC Assays for Biologic Therapies
April 23, 2025
·
2 min read
Business
Dr. M. Yaman Joins InSitu Biologics Medical Advisory Board
InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board.
April 22, 2022
·
2 min read
Press Releases
ADMA Biologics Statement on Tariffs
April 8, 2025
·
4 min read
BioMidwest
InSitu Biologics Shares Latest Investigational Work at ASRA Meeting
InSitu Biologics, Inc. will share the latest investigational work on its hydrogel-lipid-microparticle matrix at the upcoming 47th Annual Regional and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia in April 2022.
March 31, 2022
·
1 min read
Manufacturing
Merck Snaps Up WuXi Biologics Facility in Ireland for $500M
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.
January 6, 2025
·
1 min read
·
Annalee Armstrong
1 of 9,380
Next
